Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab.

Mascelli, M A; Kleiman, N S; Marciniak, S J; Damaraju, L; Weisman, H F; Jordan, R E

Mascelli, M A; Kleiman, N S; Marciniak, S J; Damaraju, L; Weisman, H F; Jordan, R E.

Affiliation

Mascelli MA; Clinical Pharmacology Department at Centocor, Malvern, PA 19335, USA. mascelli@centocor.com

Am Heart J ; 139(4): 696-703, 2000 Apr.

Article in En | MEDLINE | ID: mdl-10740154

Subject(s)

Angioplasty, Balloon, Coronary; Antibodies, Monoclonal/metabolism; Antibodies, Monoclonal/pharmacokinetics; Coronary Disease/blood; Heparin/blood; Immunoglobulin Fab Fragments/metabolism; Platelet Aggregation Inhibitors/pharmacokinetics; Platelet Aggregation/drug effects; Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors; Abciximab; Antibodies, Monoclonal/administration & dosage; Antibodies, Monoclonal/adverse effects; Coronary Disease/drug therapy; Dose-Response Relationship, Drug; Drug Interactions; Heparin/administration & dosage; Heparin/adverse effects; Humans; Immunoglobulin Fab Fragments/administration & dosage; Immunoglobulin Fab Fragments/adverse effects; In Vitro Techniques; Platelet Aggregation Inhibitors/administration & dosage; Platelet Aggregation Inhibitors/adverse effects; Platelet Glycoprotein GPIIb-IIIa Complex/metabolism

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Immunoglobulin Fab Fragments / Platelet Aggregation Inhibitors / Heparin / Angioplasty, Balloon, Coronary / Platelet Aggregation / Platelet Glycoprotein GPIIb-IIIa Complex / Coronary Disease / Antibodies, Monoclonal Limits: Humans Language: En Journal: Am Heart J Year: 2000 Document type: Article

Search on Google

XML

PubMed Links